**IHE Report** 

Prevalence of dysphagia and economic burden of aspiration pneumonia in patients with stroke or head and neck cancer

November 2019



#### INSTITUTE OF HEALTH ECONOMICS

The Institute of Health Economics (IHE) is an independent, not-for-profit organization with key competencies in health economics and decision analytic modelling, health technology assessment, and knowledge transfer/exchange. Our mission is to inform coordinated, innovative, evidence-guided health policy and practice.

#### **IHE BOARD OF DIRECTORS**

#### Chair

#### Mr. Robert Seidel, QC

#### Government and Public Authorities

Ms. Lorna Rosen – Deputy Minister, Alberta Health

**Ms. Katherine (Kate) White** – Deputy Minister, Alberta Economic Development, Trade and Tourism

Mr. Tim Murphy – VP, Health, Alberta Innovates

**Dr. Kathryn Todd** – VP Research, Innovation & Analytics, Alberta Health Services

#### Academia

**Dr. Alex Clark** – Associate VP Research, University of Alberta

**Dr. Jon Meddings** – Dean of Medicine, University of Calgary

**Dr. Brenda Hemmelgarn** – Dean of Faculty of Medicine and Dentistry, University of Alberta

Dr. Neal Davies - Dean of Pharmacy & Pharmaceutical Sciences, University of Alberta

**Dr. Braden Manns** – Svare Professor in Health Economics, University of Calgary

**Dr. Rick Szostak** – Chair, Department of Economics, University of Alberta

#### IHE

Mr. Doug Gilpin - Chair, Audit & Finance Committee

**Dr. Christopher McCabe** – Executive Director & CEO, Institute of Health Economics

Mr. John Sproule – Board Secretary; Senior Policy Director, Institute of Health Economics

**Ms.** Allison Hagen – Treasurer; Director of Finance, Operations, and Administration, Institute of Health Economics



# **IHE Report**

# Prevalence of dysphagia and economic burden of aspiration pneumonia in patients with stroke or head and neck cancer

## Prepared by:

Thomas Lo, M Clin Epi, PhD Jeff Round, PhD

**SUDA project**: This report is part of the Secondary Use Data Access (SUDA) initiative, a collaboration between the Government of Alberta (GOA) and industry that is facilitated by the IHE. The goal of the initiative is to accelerate health research, support innovation, and strengthen the health system through insights from analysis of health data. The IHE is serving as a partner to the GOA to strengthen analytic capacity and foster collaboration between the GOA, industry, and other contributors.



# **Acknowledgements**

The authors would like to thank David Onyschuk (Alberta Health) and Elizabeth Dufraine (Alberta Health) for their guidance, assistance, and comments in the preparation of this report.

The views expressed in this report are of the Institute of Health Economics.

#### **Corresponding Author**

Please direct any inquiries about this report to Jeff Round, jround@ihe.ca.

#### **Funding**

This study was supported by a financial contribution from Alberta Health.

The views expressed herein do not necessarily represent the official policy of Alberta Health.

#### **Declared Competing Interest of Authors**

Competing interest is considered to be financial interest or non-financial interest, either direct or indirect, that would affect the research contained in this report or create a situation in which a person's judgement could be unduly influenced by a secondary interest, such as personal advancement.

The authors of this publication claim no competing interest.

#### **Suggested Citation**

Lo T, Round, J. *Prevalence of dysphagia and economic burden of aspiration pneumonia in patients with stroke or head and neck cancer*. Edmonton (AB): Institute of Health Economics; 2019.

#### **License Statement and Web Address**

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (CC BY-NC-ND), a copy of which is available at <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>. This publication is available for free download from the IHE website at <a href="http://www.ihe.ca">http://www.ihe.ca</a>.

© Institute of Health Economics, 2019

This work may be copied or redistributed for non-commercial purposes, provided that attribution is given to the Institute of Health Economics. Modification is prohibited without the express written permission of the Institute of Health Economics.



# Acronyms and abbreviations

AIS acute ischemic stroke
AP aspiration pneumonia

CAD Canadian dollar

CCI Canadian Classification of Health Interventions

CMG+ case mix group

DAD Discharge Abstract Database

ED emergency department
HNC head and neck cancer
HPV human papillomavirus

ICD International Classification of Diseases

ICH intracerebral hemorrhage

ICU intensive care unit IQR interquartile range

NACRS National Ambulatory Care Reporting System

NCME nasal cavity and middle ear

SD standard deviation



# **Table of contents**

Acronyms and abbreviations	ii
Background	5
Study objectives	5
Methods	5
Data sources	5
Cohort definitions	6
Cohort A: Patients with stroke	6
Cohort B: Patients with HNC	6
Outcome variables	6
Dysphagia	6
Feeding-tube placement	6
Aspiration pneumonia	7
Hospitalization costs of AP	7
Other variables	<i>7</i>
Statistical analysis	8
Results	8
Cohort characteristics	8
Outcomes	9
Outcome 1: Dysphagia	9
Outcome 2: Feeding-tube placement	11
Outcome 3: Aspiration pneumonia	13
Summary of outcomes	16
Hospitalization costs of AP and comorbidities	17
Limitations of analysis	21
Conclusion	
Appendix A: Summary of conditions and procedures	22
Appendix B: Association between head and neck cancer and human papillomavirus infection	
Appendix C: Definition of the length of an aspiration pneumonia incident administrative data	based on
References	27



Author con	tributions	 	29
Author con	tributions	 	



## **Background**

Studies that examine the burden of dysphagia are scant; there was an incentive to study the burden of dysphagia using large, population-based administrative data. However, identifying dysphagia cases in the administrative data may be unreliable because dysphagia is underdiagnosed.<sup>1, 2</sup> González-Fernández et al. assessed the accuracy of dysphagia diagnosis in patients with stroke in the hospital data and found that it has a poor sensitivity of 23%, indicating dysphagia is undetected 77% of the time.<sup>3</sup>

Aspiration pneumonia (AP) is strongly associated with dysphagia. It is a serious acute complication of dysphagia, 4, 5 and is the main driver of hospitalization and healthcare cost for patients with dysphagia. Aspiration pneumonia has previously been studied using administrative health data. This study examined the economic burden of aspiration pneumonia using Alberta's data using a similar case-definition algorithm. Two cohorts of patients were identified and followed longitudinally because they had a higher risk of dysphagia and AP; hese cohorts were patients with stroke and patients with head and neck cancer (HNC).

# Study objectives

This study examined the prevalence of dysphagia and the economic burden of AP in patients who had stroke or HNC. Because tube feeding is recommended in patients that are at a high risk of dysphagia and/or malnutrition, placement of feeding tubes was also examined as an outcome in the two cohorts of patients.

The specific aims of this study were to estimate:

- a) the proportion of patients who had a diagnosis of dysphagia;
- b) the proportion of patients who had feeding-tube placement;
- c) the proportion of patients who had AP;
- d) the incidence of AP among these patients; and
- e) the cost of hospitalization of AP in these patients.

#### Methods

This is a retrospective cohort study utilizing Alberta's administrative health data from the calendar years of 2008 to 2018 inclusively. Two cohorts (*cohort* A = patients with stroke; *cohort* B = patients with HNC) were identified and followed longitudinally over the observation period.

#### **Data sources**

The main sources of data were: the National Ambulatory Care Reporting System (NACRS), which contains information from hospital/community-based ambulatory care including day surgeries, outpatient clinics, and emergency department (ED) visits; the Discharge Abstract Database (DAD), which contains diagnosis and procedure information about all acute care hospitalizations; the Alberta Practitioner Claims database, which provides information on reimbursement claims made by physicians for services provided to the patients; and the Alberta cancer registry database, which provides cancer diagnosis and treatment information.



#### **Cohort definitions**

#### **Cohort A: Patients with stroke**

Cohort A consisted of patients with first-diagnosed acute stroke at the ED (ambulatory care NACRS data) and/or inpatient care (DAD data). The included stroke types were acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH). Incident stroke cases were identified based on a revised algorithm (restricted to the stroke types below) used by Alberta Health and in the Interactive Health Data Application (IHDA), where the most responsible diagnosis code in DAD and NACRS for each record was scanned. The specific stroke types were AIS and ICH only. The respective International Classification of Diseases (ICD-10) codes were: 10

- H341, H342, I63, I64 for AIS; and
- I61 for ICH.

Based on the above algorithm, we identified stroke patients that had service episode start dates in the 2014 calendar year. We used the five years of preceding records (i.e., DAD and/or ED data as far back as 1 January 2009) to ascertain first-diagnosed cases. It was suggested that a five-year clearance period would include 97% of true first-diagnosed stroke cases. <sup>11</sup> Exclusion criteria of the stroke cohort include patients who were younger than 18 years of age in 2014, not presented at the ED or admitted to the hospital, other types of cerebrovascular disease (e.g., transient ischemic attack), or had HNC diagnosed in the follow-up (observation) periods. Patients who had more than one acute stroke incident were included; the first incident was used as the index diagnosis. These patients were followed for up to three years from the index date (i.e., the date when stroke was first diagnosed) or until death.

#### Cohort B: Patients with HNC

Cohort B consisted of patients with HNC identified from the cancer registry. These patients were diagnosed with HNC from the calendar year of 2008 to 2012, based on the diagnosed date. Patients were identified using the ICD-O topographical (ICD-0-3) codes. The relevant diagnostic codes are listed in Appendix A. The exclusion criteria of the HNC cohort were patients younger than 18 years of age. HNCs were also categorized into: *oral* (C00-C14), *nasal cavity and middle ear* (C30), and *larynx* (C32); or *HPV associations*. HPV association was categorized into *high, moderate*, and *other* (see Appendix B). These patients were followed for up to five years or until death.

#### **Outcome variables**

The main health outcomes in both cohorts were dysphagia, feeding-tube placement, and AP.

#### Dysphagia

The ED data (within NACRS), inpatient (DAD) data, and the physician claims data were scanned for dysphagia diagnosis. The identification of patients with dysphagia was based on ICD-10 and/or ICD-9 codes; these codes are summarized in Appendix A.

#### Feeding-tube placement

Also known as *enteral feeding*, tube feeding is the delivery of nutrition directly into the stomach or small intestine; it is a means to provide nutrients (i.e., protein, carbohydrate, fat, minerals, vitamins, and water) to individuals (e.g., post-stroke and patients with HNC) who cannot obtain nutrition entirely by mouth. To determine patients who had feeding-tube placement, the NACRS and DAD databases



were used. The relevant Canadian Classification of Health Interventions (CCI) procedure codes for gastrostomy were: 1NF53BTQB, 1NF53BTTS, 1NF53DAQB, 1NF53DATS, or 1NF53HATS. The relevant codes for jejunostomy (post-pyloric tubes) were: 1NK53BTTS, 1NK53DATS, or 1NK53HATS. The CCI codes are summarized in Appendix A.

#### **Aspiration pneumonia**

Because AP is an acute condition and a major driver of hospitalization and healthcare cost in patients with dysphagia,<sup>4-6</sup> it was assumed that the majority of patients would have visited the hospitals. The ICD-10 codes of J690, J691, or J698 were examined in both the DAD and ED data in the NACRS to identify AP presented at hospitals.<sup>7,13</sup> Physician claims data were not included in the case identification algorithm.

The cost of hospitalization for AP was estimated. Here, the unit of analysis was the AP incident. Any patient in the cohorts can have multiple AP incidents during the observation period. The start and end of an AP incident were defined based on three criteria:

- an AP diagnostic code in the hospital data that indicates the beginning of an incident;
- the duration of one AP incident cannot be shorter than 14 days; and
- an incident ends when there was no subsequent record, within 14 days, with an AP diagnostic code.

The 14-day criterion conforms to the length of antibiotic treatment (e.g., clindamycin or macrolides), which can be as long as 14 days. <sup>14</sup> Detailed information about the definition of an incident of AP can be found in Appendix C.

#### Hospitalization costs of AP

Costs per incident of AP were estimated from the payer's (Government of Alberta's) perspective. They included the direct costs of care of patients who visited the ED and/or were admitted to the hospital (i.e., inpatient cost). ED visit and inpatient costs included all costs attributable to the care of the patients, including nursing, laboratory, diagnostic imaging, drug, and supply costs. The cost of hospitalization also included the services provided by physicians that were recorded in the claims data. However, these costs may be attributable to the care of AP and/or comorbidities. The costs of ED visits (i.e., ambulatory care) and inpatient care were estimated using a top-down approach based on the case mix group (CMG+) methodology. The costs of physician services were estimated based on the actual amount paid for the services claimed. Cost estimation was based on the latest CMG+ methodology and data between the fiscal years of 2013/14 and 2017/18. All costs were adjusted to 2018 CAD using the consumer price index.

#### Other variables

Other variables included the demographic characteristics and health conditions of the patients. Demographic characteristics included sex, age, and household income. The age groups were categorized into *young-adults* (18 to 39 years), *middle-aged adults* (40 to 64 years), *young-old* (65 to 84 years), and *old-old* (85 years and older). The median household income of the dissemination areas in Alberta was estimated based on the 2016 Census data and categorized into eight income levels. Health conditions included multi-morbidity, intensive care unit (ICU) admittance during an incident of AP, and mortality. Multi-mortality was measured using the Charlson Comorbidity Index. <sup>15</sup>



#### Statistical analysis

Characteristics of the cohorts are summarized using the mean (and standard deviation [SD]) for continuous variables, and proportion for categorical variables.

The prevalence of dysphagia, enteral feeding, and AP were calculated for the two cohorts. Incidence rates of AP were calculated for the observation period.

Hospitalization cost (the sum of ED visit, inpatient, and physician costs) per AP incident calculations included the mean, SD, median, and interquartile range (IQR).

Because the cost distribution was severely positively skewed, quantile regression models were used to examine the association between costs and explanatory variables. Quantile regression does not assume normality or homoskedasticity of the distribution of cost. Explanatory variables included in the regression models were age, sex, median household income, number of comorbidities, dysphagia status, feeding tube type, stroke type (cohort A only), and cancer type and HPV association (cohort B only). Statistical significance was defined as p < 0.05.

#### **Results**

#### **Cohort characteristics**

There were 3,573 patients with first-ever stroke identified from 2014 data. The majority (88.9%) had AIS. The sex and age distributions of the patients with stroke are illustrated in Table 1.

Table 1: Characteristics of patients with stroke (N=3,573)

Table 1. Characteristics of patients with stroke (11-			
	n	%	
Stroke type			
AIS	3,176	88.9%	
ICH	397	11.1%	
Sex			
Female	1,653	46.3%	
Male	1,920	53.7%	
Age group			
18–39 years	138	3.9%	
40–64 years	1,086	30.4%	
65–84 years	1,679	47.0%	
≥85 years	670	18.8%	

AIS: acute ischemic stroke; ICH: intracerebral hemorrhage

There were 2,169 patients with HNC identified from the cancer registry from 2008 to 2012 inclusively. The majority (78.9%) had oral cancer. The characteristics of the patients with HNC are illustrated in Table 2.



Table 2: Characteristics of patients with HNC (N=2,169)

	n	%
HNC type		
Larynx	388	17.9%
NCME	70	3.2%
Oral	1,711	78.9%
Sex		
Female	1,019	47.0%
Male	1,150	53.0%
Age group		
18–39 years	99	4.6%
40–64 years	1,170	53.9%
65–84 years	784	36.2%
≥85 years	116	5.4%

NCME: nasal cavity and middle ear

#### **Outcomes**

#### Outcome 1: Dysphagia

In the patients who had the first-ever stroke in 2014, 554 had been diagnosed with dysphagia within the three-year follow-up period. Among these patients, the median time from stroke to diagnosed dysphagia was 13 days (IQR=0–121). Patients with dysphagia were more likely to be male and/or were older. The characteristics of patients with stroke, with and without dysphagia, are shown in Table 3.



Table 3: Characteristics of patients with stroke, with and without dysphagia

	With dysphagia n=554	Without dysphagia n=3,019	Chi-square test (p-value)
Stroke type			0.2176
AIS	43.9%	46.7%	
ICH	56.1%	53.3%	
Sex			0.0156*
Female	85.9%	89.4%	
Male	14.1%	10.6%	
Age group			<0.0001*
18–39 years	1.8%	4.2%	
40–64 years	24.2%	31.5%	
65–84 years	51.1%	46.2%	
≥85 years	22.9%	18.0%	

AIS: acute ischemic stroke; ICH: intracerebral hemorrhage

Among the patients with HNC in cohort B, 1,052 had dysphagia within the five-year follow-up period. The median time from HNC to diagnosed dysphagia was longer (compared to the patients with stroke) at 90 days (IQR=55–198). These patients with dysphagia were less likely to have nasal cavity and middle ear (NCME) cancer. The characteristics of patients with HNC, with and without dysphagia, are shown in Table 4.



Table 4: Characteristics of patients with HNC, with and without dysphagia

	With dysphagia n=1,052	Without dysphagia n=1,117	Chi-square test (p-value)
HNC type			0.0147*
Larynx	18.2%	17.6%	
NCME	2.1%	4.3%	
Oral	79.8%	78.1%	
Sex			0.6814
Female	47.4%	46.6%	
Male	52.6%	53.5%	
Age group			<0.0001*
18–39 years	3.0%	6.1%	
40–64 years	57.3%	50.8%	
65–84 years	35.8%	36.4%	
≥85 years	3.9%	6.7%	

NCME: nasal cavity and middle ear

#### **Outcome 2: Feeding-tube placement**

In the stroke cohort, 100 patients had a feeding-tube placement within the three-year follow-up period. Among these patients, the median time from stroke to feeding-tube placement was one day (IQR=0–52 days). Patients who had tube feeding were more likely to have had intracerebral hemorrhage (18.0% vs. 10.9%). The characteristics of patients with stroke, with and without feeding-tube placement, are illustrated in Table 5.



Table 5: Characteristics of patients with stroke, with and without feeding-tube placement

	With feeding-tube n=100	Without feeding-tube n=3,473	Chi-square test (p-value)
Stroke type			0.0262*
AIS	82.0%	89.1%	
ICH	18.0%	10.9%	
Sex			0.7971
Female	45.0%	46.3%	
Male	55.0%	53.7%	
Age group			0.0929
18–39 years	2.0%	3.9%	
40–64 years	30.0%	30.4%	
65–84 years	57.0%	46.7%	
≥85 years	11.0%	19.0%	

AIS: acute ischemic stroke; ICH: intracerebral hemorrhage

In the HNC cohort, 492 patients had a feeding-tube placement within the five-year follow-up period. The median time from HNC diagnosis to feeding-tube placement was 98 days (IQR=50–199 days). Patients who had feeding-tube placement were less likely to have NCME cancer, but were older compared to the patients without feeding-tube placement. The characteristics of patients with HNC with and without feeding-tube placement are shown in Table 6.



Table 6: Characteristics of patients with HNC, with or without feeding-tube placement

	With feeding-tube n=492	Without feeding-tube n=1,677	Chi-square test (p-value)
HNC type			0.0026*
Larynx	18.3%	17.8%	
NCME	0.8%	3.9%	
Oral	80.9%	78.3%	
Sex			0.4631
Female	45.5%	47.4%	
Male	54.5%	52.6%	
Age group			0.0017*
18–39 years	3.9%	4.8%	
40–64 years	57.3%	53.0%	
65–84 years	36.8%	36.0%	
≥85 years	2.0%	6.3%	

NCME: nasal cavity and middle ear

#### **Outcome 3: Aspiration pneumonia**

In the stroke cohort, 141 patients (3.9%) had AP presented at a hospital within the follow-up period. The median time from stroke to diagnosed AP was 90 days (IQR=0–528 days). The patients who had diagnosed AP were more likely to be older. The characteristics of patients with stroke, with and without diagnosed AP, are illustrated in Table 7.



Table 7: Characteristics of patients with stroke, with and without aspiration pneumonia

	With aspiration pneumonia n=141	Without aspiration pneumonia n=3,432	Chi-square test (p-value)
Stroke type  AIS	91.5%	88.8%	0.3161
ICH	8.5%	11.2%	
Sex			0.2828
Female	41.8%	46.5%	
Male	58.2%	53.6%	
Age group			0.0013*
18–39 years	0.7%	4.0%	
40–64 years	19.2%	30.9%	
65–84 years	53.9%	46.7%	
≥85 years	26.2%	18.4%	

AIS: acute ischemic stroke; ICH: intracerebral hemorrhage

Among the patients with stroke who had AP, 167 incidents were identified. The mean number of AP incidents per patient with stroke was 1.22 (SD=0.74). The majority of these patients (86.86%) had only one AP incident. The estimated mean hospital length of stay per AP incident was 26.54 (SD=74.09) days. At the time of the incident, patients with stroke had an average CCI score of 2.18 (SD=1.96). The most common comorbidity group was cerebrovascular diseases, followed by diabetes with complications. The five most common comorbidity groups are illustrated in Table 8.

Table 8: Top five comorbidity groups in patients with stroke diagnosed at an aspiration pneumonia incident

Comorbidity	%
Cerebrovascular disease	43.7%
Diabetes with complications	22.8%
Chronic pulmonary disease	18.6%
Congestive heart failure	17.4%
Dementia	16.2%

In the HNC cohort, 146 patients (6.7%) had AP within the follow-up period. The median time from HNC to diagnosed AP was 334 days (IQR=129–843 days). About 50% of patients who had AP were in the 65 to 84 years age groups. In contrast, the majority of HNC patients without AP (approximately



60%) were under 65 years old. The characteristics of patients with HNC, with and without diagnosed AP, are shown in Table 9.

Table 9: Characteristics of HNC patients, with and without aspiration pneumonia

	With aspiration pneumonia n=146	Without aspiration pneumonia n=2023	Chi-square test ( <i>p</i> -value)
HNC type			0.1068
Larynx	23.3%	17.5%	
NCME	1.4%	3.4%	
Oral	75.3%	79.1%	
Sex			0.1062
Female	53.5%	46.5%	
Male	46.6%	53.5%	
Age group			0.0002*
18–39 years	0.0%	4.9%	
40–64 years	43.8%	54.7%	
65–84 years	50.7%	35.1%	
≥85 years	5.5%	5.3%	

NCME: nasal cavity and middle ear

Among patients with HNC with AP, 168 AP incidents were identified in the hospital data. The mean number of incidents per patient was 1.18 (SD=0.50). The majority of these patients (85.9%) had only one AP incident. The estimated mean hospital length of stay per AP incident was 21.10 (SD=34.58) days. At the time of the incident, patients with HNC had an average CCI score of 2.14 (SD=2.75) (note: Cancer and carcinoma metastasis groups of diseases were excluded from the CCI calculation.) The most common comorbidity group was chronic pulmonary diseases, followed by diabetes without complications. The five most common comorbidity groups are illustrated in Table 10.

Table 10: Top five comorbidity groups in patients with HNC diagnosed at an aspiration pneumonia incident

Comorbidity	%
Chronic pulmonary disease	22.6
Diabetes without complications	11.9
Diabetes with complications	7.7
Congestive heart failure	6.6
Myocardial infarction	5.4



#### **Summary of outcomes**

While 17.5% of patients with stroke had diagnosed dysphagia, feeding-tube placement, and/or AP, 53.3% of patients with HNC had one or more of these conditions. The results of the three outcomes for both cohorts are summarized in Table 11.

Table 11: Prevalence of dysphagia, feeding-tube placement, and/or aspiration pneumonia in

patients with stroke or HNC

	Patients with stroke	Patients with HNC
Dysphagia	_	l
n (%)	554 (15.5%)	1,052 (48.5%)
Female	13.3%	23.0%
Male	2.2%	25.5%
18–39 years	0.3%	1.4%
40–64 years	3.8%	27.8%
65–84 years	7.9%	17.4%
≥85 years	3.6%	1.9%
Feeding-tube placer	nent	
n (%)	100 (2.8%)	492 (22.7%)
Female	1.3%	10.3%
Male	1.5%	12.4%
18–39 years	0.1%	0.9%
40–64 years	0.8%	13.0%
65–84 years	1.6%	8.3%
≥85 years	0.3%	0.5%
Aspiration pneumon	ia	
n (%)	141 (3.9%)	146 (6.7%)
Female	1.6%	3.6%
Male	2.3%	3.1%
18–39 years	0.0%	0.0%
40–64 years	0.8%	3.0%
65–84 years	2.1%	3.4%
≥85 years	1.0%	0.4%

Note: Patients with stroke were followed three years; patients with HNC were followed five years.



# Hospitalization costs of AP and comorbidities

The mean hospitalization cost (the sum of ED visit, inpatient, and physician costs) of an AP incident in patients who had stroke was estimated at \$32,219 (2018 CAD). Cost distribution was severely positively skewed; the median (IQR) cost per incident was estimated at \$12,063. Inpatient cost (including nursing, laboratory, diagnostic imaging, drug, and supply costs) was the biggest component (89.2%) of total hospitalization costs, followed by physician costs (9.7%) and ED costs (1.1%). In Alberta, AP in patients with stroke cost the government approximately \$1.8 million per year. Descriptive statistics of hospitalization cost and the component breakdown are shown in Table 12.

Table 12: Costs of hospitalization for aspiration pneumonia in patients with stroke

Hospitalization cost component	Cost (2018 CAD)	SD or IQR
Emergency departmen	t	
Mean (SD)	\$367	(481)
Median (IQR)	\$0	(0-817)
Inpatient		
Mean (SD)	\$28,725	(67,835)
Median (IQR)	\$8,378	(2,346–26,376)
Physician		
Mean (SD)	\$3,127	(4,765)
Median (IQR)	\$1,516	(575–3,637)
Total		
Mean (SD)	\$32,219	(67,653)
Median (IQR)	\$12,063	(5,550–30,864)

Note: Costs may be attributable to the treatment of AP and/or comorbidities.

IQR: interquartile range; SD: standard deviation

The mean hospitalization cost for AP in the HNC cohort was estimated at \$21,828 (2018 CAD); the median cost per incident was \$8,794. Similar to that in the stroke cohort, inpatient cost was the biggest component (85.0%) of the total cost, followed by physician costs (13.0%) and ED costs (2.0%). Aggregated at the population level, AP incidents in patients with HNC cost the Alberta government over \$730,000 annually. Descriptive statistics of the cost breakdown can be found in Table 13.



Table 13: Costs of hospitalization for aspiration pneumonia in patients with HNC

Hospitalization cost component	Cost (2018 CAD)	SD or IQR
Emergency department	nt	
Mean (SD)	\$445	(513)
Median (IQR)	\$0	(0-833)
Inpatient		
Mean (SD)	\$19,320	(29,704)
Median (IQR)	\$7,178	(1,775–22,938)
Physician		
Mean (SD)	\$2,965	(3,387)
Median (IQR)	\$1,121	(347–2,027)
Total		
Mean (SD)	\$21,828	(32,131)
Median (IQR)	\$8,794	(2,902–24,590)

Note: Costs may be attributable to the treatment of AP and/or comorbidities.

IQR: interquartile range; SD: standard deviation

Regression analysis results show that none of the included independent variables were statistically significantly associated with hospitalization cost in either the models. Nonetheless, in the regression model that included patients with stroke, the signs of the coefficients suggest a positive relationship between cost and the oldest age group, lower income levels, AIS stroke type (relative to ICH), feeding-tube placement, number of comorbidities, and/or mortality (see Table 14). Results also suggest that costs were negatively associated with female sex, dysphagia diagnosis, and/or ICU admittance. However, statistical tests were not significant for any explanatory variables.

In the regression model that included patients with HNC, the signs of the coefficients suggest that lower age groups, higher income levels, cancer in NCME (relative to oral cancer), HPV association, tube feeding, and ICU admittance were positively related to costs, while female sex, cancer in the larynx, dysphagia diagnosis, and number of comorbidities were negatively related to costs (see Table 15).



Table 14: Median regression results for hospitalization costs of aspiration pneumonia

incidents in patients with stroke

Variable	Coefficient	95% CI	<i>p</i> -value
Sex			
Female	-5,013	-11,625, 1,599	0.1362
Age group			1
18–39	-5,409	-71,104, 60,287	0.8709
40–64	-5,159	-16,118, 5,800	0.3536
65–84	-4,787	-16,679, 7,105	0.4274
≥85 (ref.)			
Income level			
>200,000 (ref.)			
150,000–200,000	-1,811	-15,042, 11,419	0.787
120,000–150,000	-2,769	-14,613, 9,075	0.6447
90,000–120,000	1,085	-14,060, 16,231	0.8875
60,000–90,000	2,792	-10,463.63, 16,048	0.6777
30,000–60,000	731	-18,882, 20,344	0.9414
<30,000	2,182	-28,525, 32,888	0.8885
Stroke type			
ICH (ref.)			
AIS	3,644	-6,994, 14,282	0.4994
Other			
Dysphagia	-451	-13,030, 12,128	0.9435
Tube feeding	12,809	-56,562, 82,180	0.7156
No. comorbidities	2,233	-614, 5,080	0.1233
ICU admitted	-144	-10,887, 10,600	0.9789
Mortality	1,594	-86,940, 90,128	0.9717

AIS: acute ischemic stroke; CI: confidence interval; ICH: intracerebral hemorrhage; ICU: intensive care unit



Table 15: Median regression results for hospitalization costs of aspiration pneumonia incidents in patients with HNC

Female         -3,164         -45,387,39,059         0.877           Age group         18–39         NA	Variable	Coefficient	95% CI	<i>p</i> -value
Age group  18–39 NA NA  40–64 77,003 −41,072, 195,078 0.1882  65–84 75,386 −69,965, 220,736 0.2913  ≥85 (ref.)  Income level  ≥200,000 (ref.)  150,000−200,000 18,012 −90,245, 126,268 0.7315  120,000−150,000 20,132 −79,029, 119,292 0.6757  90,000−120,000 6,661 −94,292, 107,615 0.8916  30,000−60,000 21,718 −109,573, 153,009 0.733  <30,000 21,937 −109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx −4,355 −58,949, 50,240 0.8692  NCME 75,177 −124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 −78,973, 88,501 0.9065  High 16,809 −53,622, 87,239 0.6231  Other  Dysphagia −5,577 −44,036, 32,881 0.7648  Tube feeding 6,681 −28,396, 41,757 0.6946  No. comorbidities −1,741 −20,944, 17,462 0.8515	Sex			
18–39         NA         NA         NA           40–64         77,003         −41,072, 195,078         0.1882           65–84         75,386         −69,965, 220,736         0.2913           ≥85 (ref.)         Income level           ≥200,000 (ref.)         150,000–200,000         18,012         −90,245, 126,268         0.7315           120,000–150,000         20,132         −79,029, 119,292         0.6757           90,000–120,000         20,841         −67,545, 109,226         0.6273           60,000–90,000         6,661         −94,292, 107,615         0.8916           30,000–60,000         21,718         −109,573, 153,009         0.733           <30,000	Female	-3,164	-45,387, 39,059	0.877
40-64 77,003 -41,072, 195,078 0.1882 65-84 75,386 -69,965, 220,736 0.2913 ≥85 (ref.)  Income level  >200,000 (ref.)  150,000-200,000 18,012 -90,245, 126,268 0.7315 120,000-150,000 20,132 -79,029, 119,292 0.6757 90,000-120,000 6,661 -94,292, 107,615 0.8916 30,000-60,000 21,718 -109,573, 153,009 0.733 <30,000 21,937 -109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx -4,355 -58,949, 50,240 0.8692  NCME 75,177 -124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 -78,973, 88,501 0.9065  High 16,809 -53,622, 87,239 0.6231  Other  Dysphagia -5,577 -44,036, 32,881 0.7648  Tube feeding 6,681 -28,396, 41,757 0.6946  No. comorbidities -1,741 -20,944, 17,462 0.8515	Age group			
65–84 75,386 −69,965, 220,736 0.2913 ≥85 (ref.)  Income level  >200,000 (ref.)  150,000–200,000 18,012 −90,245, 126,268 0.7315  120,000–150,000 20,132 −79,029, 119,292 0.6757  90,000–120,000 20,841 −67,545, 109,226 0.6273  60,000–90,000 6,661 −94,292, 107,615 0.8916  30,000–60,000 21,718 −109,573, 153,009 0.733  <30,000 21,937 −109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx −4,355 −58,949, 50,240 0.8692  NCME 75,177 −124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 −78,973, 88,501 0.9065  High 16,809 −53,622, 87,239 0.6231  Other  Dysphagia −5,577 −44,036, 32,881 0.7648  Tube feeding 6,681 −28,396, 41,757 0.6946  No. comorbidities −1,741 −20,944, 17,462 0.8515	18–39	NA	NA	NA
≥85 (ref.)  Income level  >200,000 (ref.)  150,000–200,000  18,012  -90,245, 126,268  0.7315  120,000–150,000  20,132  -79,029, 119,292  0.6757  90,000–120,000  6,661  -94,292, 107,615  0.8916  30,000–60,000  21,718  -109,573, 153,009  0.733  <30,000  21,937  -109,067, 152,940  0.7298  HNC type  Oral (ref.)  Larynx  -4,355  -58,949, 50,240  0.8692  NCME  75,177  -124,734, 275,088  0.4409  HPV association  Low (ref.)  Moderate  4,764  -78,973, 88,501  0.9065  High  16,809  -53,622, 87,239  0.6231  Other  Dysphagia  -5,577  -44,036, 32,881  0.7648  Tube feeding  6,681  -28,396, 41,757  0.6946  No. comorbidities  -1,741  -20,944, 17,462  0.8515	40–64	77,003	-41,072, 195,078	0.1882
Section   Sect	65–84	75,386	-69,965, 220,736	0.2913
>200,000 (ref.)  150,000–200,000  18,012  -90,245, 126,268  0.7315  120,000–150,000  20,132  -79,029, 119,292  0.6757  90,000–120,000  20,841  -67,545, 109,226  0.6273  60,000–90,000  6,661  -94,292, 107,615  0.8916  30,000–60,000  21,718  -109,573, 153,009  0.733  <30,000  21,937  -109,067, 152,940  0.7298  HNC type  Oral (ref.)  Larynx  -4,355  -58,949, 50,240  0.8692  NCME  75,177  -124,734, 275,088  0.4409  HPV association  Low (ref.)  Moderate  4,764  -78,973, 88,501  0.9065  High  16,809  -53,622, 87,239  0.6231  Other  Dysphagia  -5,577  -44,036, 32,881  0.7648  Tube feeding  6,681  -28,396, 41,757  0.6946  No. comorbidities  -1,741  -20,944, 17,462  0.8515	≥85 (ref.)			
150,000–200,000	Income level			
120,000–150,000       20,132       -79,029, 119,292       0.6757         90,000–120,000       20,841       -67,545, 109,226       0.6273         60,000–90,000       6,661       -94,292, 107,615       0.8916         30,000–60,000       21,718       -109,573, 153,009       0.733         <30,000	>200,000 (ref.)			
90,000–120,000 20,841 -67,545, 109,226 0.6273 60,000–90,000 6,661 -94,292, 107,615 0.8916 30,000–60,000 21,718 -109,573, 153,009 0.733 <30,000 21,937 -109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx -4,355 -58,949, 50,240 0.8692  NCME 75,177 -124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 -78,973, 88,501 0.9065  High 16,809 -53,622, 87,239 0.6231  Other  Dysphagia -5,577 -44,036, 32,881 0.7648  Tube feeding 6,681 -28,396, 41,757 0.6946  No. comorbidities -1,741 -20,944, 17,462 0.8515	150,000–200,000	18,012	-90,245, 126,268	0.7315
60,000–90,000 6,661 -94,292, 107,615 0.8916 30,000–60,000 21,718 -109,573, 153,009 0.733 <30,000 21,937 -109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx -4,355 -58,949, 50,240 0.8692  NCME 75,177 -124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 -78,973, 88,501 0.9065  High 16,809 -53,622, 87,239 0.6231  Other  Dysphagia -5,577 -44,036, 32,881 0.7648  Tube feeding 6,681 -28,396, 41,757 0.6946  No. comorbidities -1,741 -20,944, 17,462 0.8515	120,000–150,000	20,132	-79,029, 119,292	0.6757
30,000–60,000 21,718 —109,573, 153,009 0.733  <30,000 21,937 —109,067, 152,940 0.7298  HNC type  Oral (ref.)  Larynx —4,355 —58,949, 50,240 0.8692  NCME 75,177 —124,734, 275,088 0.4409  HPV association  Low (ref.)  Moderate 4,764 —78,973, 88,501 0.9065  High 16,809 —53,622, 87,239 0.6231  Other  Dysphagia —5,577 —44,036, 32,881 0.7648  Tube feeding 6,681 —28,396, 41,757 0.6946  No. comorbidities —1,741 —20,944, 17,462 0.8515	90,000–120,000	20,841	-67,545, 109,226	0.6273
<30,000	60,000–90,000	6,661	-94,292, 107,615	0.8916
HNC type  Oral (ref.)  Larynx	30,000–60,000	21,718	-109,573, 153,009	0.733
Oral (ref.)       —4,355       —58,949, 50,240       0.8692         NCME       75,177       —124,734, 275,088       0.4409         HPV association       ————————————————————————————————————	<30,000	21,937	-109,067, 152,940	0.7298
Larynx       -4,355       -58,949, 50,240       0.8692         NCME       75,177       -124,734, 275,088       0.4409         HPV association       Low (ref.)         Moderate       4,764       -78,973, 88,501       0.9065         High       16,809       -53,622, 87,239       0.6231         Other         Dysphagia       -5,577       -44,036, 32,881       0.7648         Tube feeding       6,681       -28,396, 41,757       0.6946         No. comorbidities       -1,741       -20,944, 17,462       0.8515	HNC type	· · · · · ·		<u>.</u>
NCME       75,177       -124,734, 275,088       0.4409         HPV association       Low (ref.)       Outleast       4,764       -78,973, 88,501       0.9065         High       16,809       -53,622, 87,239       0.6231         Other       Other       -44,036, 32,881       0.7648         Tube feeding       6,681       -28,396, 41,757       0.6946         No. comorbidities       -1,741       -20,944, 17,462       0.8515	Oral (ref.)			
HPV association  Low (ref.)  Moderate 4,764 -78,973, 88,501 0.9065  High 16,809 -53,622, 87,239 0.6231  Other  Dysphagia -5,577 -44,036, 32,881 0.7648  Tube feeding 6,681 -28,396, 41,757 0.6946  No. comorbidities -1,741 -20,944, 17,462 0.8515	Larynx	-4,355	-58,949, 50,240	0.8692
Low (ref.)         Moderate       4,764       -78,973, 88,501       0.9065         High       16,809       -53,622, 87,239       0.6231         Other         Dysphagia       -5,577       -44,036, 32,881       0.7648         Tube feeding       6,681       -28,396, 41,757       0.6946         No. comorbidities       -1,741       -20,944, 17,462       0.8515	NCME	75,177	-124,734, 275,088	0.4409
Moderate       4,764       -78,973, 88,501       0.9065         High       16,809       -53,622, 87,239       0.6231         Other         Dysphagia       -5,577       -44,036, 32,881       0.7648         Tube feeding       6,681       -28,396, 41,757       0.6946         No. comorbidities       -1,741       -20,944, 17,462       0.8515	HPV association			
High     16,809     -53,622, 87,239     0.6231       Other       Dysphagia     -5,577     -44,036, 32,881     0.7648       Tube feeding     6,681     -28,396, 41,757     0.6946       No. comorbidities     -1,741     -20,944, 17,462     0.8515	Low (ref.)			
Other       Dysphagia     -5,577     -44,036, 32,881     0.7648       Tube feeding     6,681     -28,396, 41,757     0.6946       No. comorbidities     -1,741     -20,944, 17,462     0.8515	Moderate	4,764	-78,973, 88,501	0.9065
Dysphagia         -5,577         -44,036, 32,881         0.7648           Tube feeding         6,681         -28,396, 41,757         0.6946           No. comorbidities         -1,741         -20,944, 17,462         0.8515	High	16,809	-53,622, 87,239	0.6231
Tube feeding 6,681 -28,396, 41,757 0.6946  No. comorbidities -1,741 -20,944, 17,462 0.8515	Other			
No. comorbidities -1,741 -20,944, 17,462 0.8515	Dysphagia	-5,577	-44,036, 32,881	0.7648
	Tube feeding	6,681	-28,396, 41,757	0.6946
ICU admitted 128,272 -16,973, 273,517 0.0802	No. comorbidities	-1,741	-20,944, 17,462	0.8515
	ICU admitted	128,272	-16,973, 273,517	0.0802

CI: confidence interval; ICU: intensive care unit; NA: not available; NCME: nasal cavity and middle ear



# **Limitations of analysis**

Because administrative health data were not originally collected for research purposes, there are some limitations in the analysis of this study. Identification of the two cohorts of patients (i.e., with stroke and HNC) and the outcome relied on contacts with the health care system and information in the data (e.g., records of diagnosis). Not all patients with a specific condition, such as dysphagia, have seen a doctor and/or diagnosed. Hence, the prevalence and incidence measures in this study were likely underestimated.

Cost estimates in this study were for AP and comorbidity present at the time of the incidents. Although some precautions (e.g., the use of most responsible diagnosis and diagnosis type) were taken during the ascertainment of AP incidents and costs, because each episode of healthcare contact can associate with multiple diagnoses, it was impossible to allocate the cause of contact (or costs) to one specific condition. Additionally, the follow-up periods were different for the two cohorts; any comparison of results made between the stroke and HNC cohorts must be interpreted with caution.

Several factors might have affected the regression analysis results. While data of the independent variables (in the regression models) were extracted at the individual level, inpatient and ED costs were estimated using a top-down approach based on group averages (CMG+); this approach could have diluted the true variance of costs between patients. In some variables, there might have been too few occurrences (e.g., only three stroke patients died during an AP incident) to yield any statistically significant findings.

#### Conclusion

The number of first-ever AIS and ICH was 3,573 per year, based on 2014 Alberta data. Administrative health data indicate 15.5% of these patients were diagnosed with dysphagia within a three-year follow-up period, while 17.5% had either dysphagia, tube feeding, and/or AP. Because tube feeding and AP are strongly associated with dysphagia, the number of patients with diagnosed dysphagia was likely underestimated.

About 434 patients were diagnosed with HNC per year between 2008 and 2012 in Alberta. Among these patients, nearly half (48.5%) were diagnosed with dysphagia in a five-year follow up, while 53.3% had either dysphagia, tube feeding, and/or AP.

The hospitalization cost of AP was estimated at \$32,219 (2018 CAD) in patients with stroke and \$21,828 (2018 CAD) in patients with HNC. When multiplying these costs by the number of AP incidents per year (both stroke and HNC cohorts), the annual costs to the Alberta government were \$1.8 million and \$730,000 respectively.

The regression analysis did not find any statistically significant explanatory variable of cost in this study.



# **Appendix A: Summary of conditions and procedures**

#### **Acute stroke**

Table A.1: Stroke and associated diagnostic codes

Sub-group	ICD-9-CM	ICD-10-CA
Arterial ischemic stroke (AIS)		
AIS - Retinal vascular occlusion	362.3	H34.1, H34.2
AIS - Occlusion and stenosis of precerebral arteries	433.x1	I63.x
AIS - Occlusion of cerebral arteries	434.x1	I64.x
AIS - Acute, but ill-defined cerebrovascular disease	436	NA
Intracerebral hemorrhage (ICH)	431.x	I61.x
Subarachnoid hemorrhage (SAH)	430.x	I60.x



# Head and neck cancers

Table A.2: Head and neck cancers and associated two-digit ICD-O-3 codes

Sub-group	ICD-O-3 Topographical	AHS cancer type
Lip	C00	Oral
Base of tongue	C01	Oral
Other and unspecified parts of tongue	C02	Oral
Gum	C03	Oral
Floor of month	C04	Oral
Palate	C05	Oral
Other and unspecified parts of mouth	C06	Oral
Parotid gland	C07	Oral
Other and unspecified major salivary glands	C08	Oral
Tonsil	C09	Oral
Oropharynx	C10	Oral
Nasopharynx	C11	Oral
Pyriform sinus	C12	Oral
Hypopharynx	C13	Oral
Other and ill-defined sites in lip, oral cavity, and pharynx	C14	Oral
Nasal cavity and middle ear	C30	NCME
Larynx	C32	Larynx



# Dysphagia and aspiration pneumonia

Table A.3: Dysphagia and aspiration pneumonia and associated diagnostic codes

Condition	ICD-9-CM	ICD-10-CA
Dysphagia	787.2	R13.0, R13.2, R13.8
Aspiration pneumonia	507.0, 507.1, 507.8	J69.0, J69.1, J69.8

# Feeding-tube placement

Table A.4: Feeding-tube placement and associated procedure codes

Sub-group	CCI
Gastrostomy (G-tubes)	1.NF.53.^^, 1.NF.53.BT-TS, 1.NF.53.BT-QB, 1.NF.53.DA- TS, 1.NF.53.DA-QB, 1.NF.53.HA-TS
Jejunostomy (J-tubes)	1.NK.53.^^, 1.NK.53.BT-TS, 1.NK.53.DA-TS, 1.NK.53.HA-TS



# Appendix B: Association between head and neck cancer and human papillomavirus infection

Table B.1: Association between head and neck cancer (based on 3-digit ICD-O-3 codes) and human papillomavirus infection

HPV association	ICD-O-3 codes
High	C01.9, C02.4, C05.1, C05.2, C09.0-10.3, C10.8-10.9, C14.0, C14.2
Moderate	C00.3-00.4, C02.0-C02.3, C02.9-C03.1, C03.9-C04.1, C04.9-C05.0, C05.9-C06.2, C06.9
Low	C11.0-C13.9, C30.0, C32.0-C32.9

Adapted from: Johnson-Obaseki et al. (2012)16

HPV: human papillomavirus



# Appendix C: Definition of the length of an aspiration pneumonia incident based on administrative data

Length of an AP incident is calculated in days. The start of an incident was marked by a record in the NACRS (ED data only) or DAD data with a most responsible diagnosis (MRDx) or type 1 diagnosis ("a condition that impacted care, i.e. a significant comorbidity, and was present prior to hospital admission") of AP. This is because an AP can be induced by an intervention (e.g., tube feeding) and/or presented after hospital admission. Each hospital record has a start (and end) date; the start date was used to proxy the beginning of an AP incident.

It was assumed an incident of AP cannot be ≤14 days because antibiotic treatment of pneumonia (including AP) can be as long as 14 days. For example, if data indicated a patient visited the ED with a diagnosis of AP and was discharged home the same day without a hospital admission, then the length of this AP incident is 14 days. The length of an AP incident can also be different from the length the patient spent at the hospital because a person can be discharged (after hospitalization) home before the end of their pharmacotherapy for AP. Though the person can remain in a hospital for other treatments, the end of an incident was marked by discharge date of hospital record (ED or inpatient) due to data limitations, provided that there has been ≥14 days since the beginning of the incident.

An incident did not necessary end at discharge (home) of the same hospital stay. Instead, it ended when the data indicated the patient has no subsequent AP diagnosis and/or the next record was >14 days. The 14-day cut-off was used because it was assumed that recovery from an AP took at least 14 days.



#### References

- 1. Martino R, Martin RE, Black S. Dysphagia after stroke and its management. *CMAJ* 2012;184(10):1127-8.
- 2. González-Fernández M, Humbert I, Winegrad H, Cappola AR, Fried LP. Dysphagia in oldold women: Prevalence as determined according to self-report and the 3-ounce water swallowing test. J Am Geriatr Soc 2014;62(4):716-20.
- 3. González-Fernández M, Gardyn M, Wyckoff S, Ky PK, Palmer JB. Validation of ICD-9 Code 787.2 for identification of individuals with dysphagia from administrative databases. *Dysphagia* 2009;24(4):398-402.
- 4. van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, Schols JM, de Baat C. Metaanalysis of dysphagia and aspiration pneumonia in frail elders. *J Dent Res* 2011;90(12):1398-404.
- 5. Waters TM, Logemann JA, Pauloski BR, Rademaker AW, Lazarus CL, Newman LA, et al. Beyond efficacy and effectiveness: Conducting economic analyses during clinical trials. *Dysphagia* 2004;19(2):109-19.
- 6. Bonilha HS, Simpson AN, Ellis C, Mauldin P, Martin-Harris B, Simpson K. The one-year attributable cost of post-stroke dysphagia. *Dysphagia* 2014;29(5):545-52.
- 7. Wu CP, Chen YW, Wang MJ, Pinelis E. National trends in admission for aspiration pneumonia in the United States, 2002–2012. *Ann Am Thorac Soc* 2017;14(6):874-9.
- 8. Hall SF, Griffiths RJ. Evaluation of treatment outcomes in patients with supraglottic laryngeal cancer in Ontario, Canada: A population-based study. *Head Neck* 2018;40(5):1024-33.
- 9. Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, et al. Aspiration pneumonia after chemo–intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. *Head Neck* 2014;36(1):120-5.
- 10. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. *Stroke* 2005;36(8):1776-81.
- 11. Katzenellenbogen JM, Somerford P, Semmens JB, Codde JP. Effect of clearance periods on hospital stroke incidence using linked administrative data. *Int J Stroke* 2010;5(4):336-7.
- 12. Joundi RA, Saposnik G, Martino R, Fang J, Porter J, Kapral MK. Outcomes among patients with direct enteral vs nasogastric tube placement after acute stroke. *Neurology* 2018;90(7):e544-52.
- 13. Palmer WL, Bottle A, Davie C, Vincent CA, Aylin P. Meeting the ambition of measuring the quality of hospitals' stroke care using routinely collected administrative data: A feasibility study. *Int J Qual Health Care* 2013;25(4):429-36.
- 14. Toward Optimized Practice (TOP). Guideline for the diagnosis and management of community acquired pnuemonia: Adult. Edmonton (AB): TOP; 2008.
- 15. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005:1130-9.



16. Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: Trends 1992 to 2007. *Otolaryngol Head Neck Surg* 2012;147(1):74-8.



# **Author contributions**

Thomas Lo contributed to study conception and design, data collection and analysis, interpretation, and revisions of the report, and approved the final version.

Jeff Round contributed to critical review of the report, and approved the final version.



Institute of Health Economics 1200 – 10405 Jasper Avenue Edmonton AB Canada T5J 3N4 Tel. 780.448.4881 Fax. 780.448.0018 info@ihe.ca

www.ihe.ca